NeraCare
PrivateLast Round
Series A
Mar 11, 2020
Total Funding Raised
$9.04M
Company Overview
NeraCare is a biotechnology company that develops and commercializes molecular diagnostic tests for personalized survival prediction in melanoma patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeraCare Comparables
Compare NeraCare with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AMLo Biosciences | 84% | |
| SkylineDx | 84% | |
| Castle Biosciences, Inc. | 77% |
NeraCare Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 11, 2020 |
Key People
Founding team and executive leadership
NeraCare Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BayBG Bayerische Beteiligungsgesellschaft | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 11, 2020
$9M round led by mig-fonds-10-14-and-16
NeraCare Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access